Monopar Therapeutics

Monopar Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. engages in building a drug development pipeline through the licensing and acquisition of oncology therapeutics in late preclinical and clinical development stages. Its product pipeline includes Validive, Camsirubicin and MNPR-101. The company was founded by Chandler D. Robinson, Christopher M. Starr and Andrew P. Mazar in December 2014 and is headquartered in Wilmette, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Monopar Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing proprietary therapeutics for cancer patients. It also focuses on building a drug development pipeline through the licensing, and acquisition of therapeutics in late preclinical and clinical development stages. The company was founded by Chandler Drew Robinson, Christopher M. Starr and Andrew P. Mazar in December 2014 and is headquartered in Wilmette, IL.

There are currently no FDA-approved drugs to prevent or treat chemoradiotherapy-induced SOM

Monopar Announces Initiation of its Phase 2b/3 (VOICE) Trial to Evaluate Validive® for the Prevention of Chemoradiotherapy-Induced Severe Oral Mucositis (SOM) in Oropharyngeal Cancer (OPC)

Validive ® Phase 2b/3 Clinical Trial on Track to Start Before Year-end Issuance of New Patents For Validive Camsirubicin Phase 2 Clinical Trial to Start Late 2020/Early 2021

Monopar Therapeutics Reports Third Quarter 2020 Financial Results and Business Update

Strengthens Monopar's Validive IP Portfolio To 2035 Strengthens Monopar's Validive IP Portfolio To 2035

Monopar Announces Issuance of New Patents Broadening Protections For Phase 2b/3 Clinical-Stage Lead Product Candidate Validive®

WILMETTE, Ill., Sept.  14, 2020  (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) today announced that Chandler D. Robinson, MD, Chief Executive Officer, will present a corporate update at the H.C. Wainwright 22nd Annual Global Investment Conference, Healthcare & Biotech Track. The conference will be held virtually.

Monopar Therapeutics to Present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 16, 2020

WILMETTE, Ill., BELOIT, Wis. and TYLER, Texas, Sept.  09, 2020  (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) and NorthStar Medical Radioisotopes, LLC, which are jointly developing urokinase plasminogen activator receptor targeted radio-immuno-therapeutics (uPRITs) for the potential treatment of patients with severe COVID-19, today announced a collaboration with The University of Texas Health Science Center at Tyler (UTHSCT) and its Texas Lung Injury Institute (TLII). UTHSCT is planning to perform in vitro and in vivo studies through the TLII and participate in the clinical development of uPRITs for the treatment of severe COVID-19 through its medical center.

Monopar and NorthStar Collaborating with Texas Lung Injury Institute for Testing of Novel Potential Therapeutic for Severe COVID-19

WILMETTE, Ill. and BELOIT, Wis. and MORGAN HILL, Calif., Aug.  19, 2020  (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (Wilmette, IL) and NorthStar Medical Radioisotopes, LLC (Beloit, WI), who are collaborating on the development of urokinase plasminogen activator receptor targeted radio-immuno-therapeutics (uPRITs) for the potential treatment of patients with severe COVID-19, today announced a partnership with Aragen Bioscience, Inc. (Morgan Hill, CA),  a leading contract research organization focused on accelerating preclinical biologics product development. Aragen will perform studies aimed at selecting a lead candidate uPRIT to advance into IND-enabling development for severe COVID-19.

Monopar and NorthStar Partner with Aragen for Testing of Novel Potential Therapeutic for Severe COVID-19

Cars.com

Ford Motor Company

Identiv

Kinross Gold

LiveXLive Media

Limelight Networks

Teva Pharmaceutical

Due to the disjointed fundamentals, many investors were caught off guard with this current bull market. However, there are cheap stocks to buy that are still available.

8 Cheap Stocks to Keep on Your Short List

Albertsons Companies

Home Depot

Lululemon Athletica

Sociedad Quimica Y Minera De Chile

Smith & Wesson Brands

Teladoc

Wheaton Precious Metals

With rising coronavirus hospitalizations dominating headlines, investors will shift back toward a pandemic mentality. Here are nine stocks to buy to capitalize on this trend.

9 Stocks to Buy for a Wild Ride in August

Potential Companion Diagnostic to Monopar’s uPRIT Program Potential Companion Diagnostic to Monopar’s uPRIT Program

Monopar Announces Plan to Advance Development of Novel Triage Test for Severe COVID-19 Utilizing its Patented Technology

WILMETTE, Ill. and BELOIT, Wis. and ANGLETON, Texas, Aug.  10, 2020  (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (Wilmette, IL) and NorthStar Medical Radioisotopes, LLC (Beloit, WI), who are collaborating on the development of Radio-Immuno-Therapeutics (RITs) to treat patients with severe COVID-19, today announced a partnership with IsoTherapeutics Group, LLC (Angleton, TX), to develop and manufacture a RIT for the potential treatment of severe COVID-19.

Monopar and NorthStar Partner with IsoTherapeutics for the Manufacturing of Potential Therapeutic for Severe COVID-19

Collaboration Formed to Develop COVID-19 Therapeutic with Monopar’s Proprietary MNPR-101 Technology Collaboration Formed to Develop COVID-19 Therapeutic with Monopar’s Proprietary MNPR-101 Technology

Monopar Therapeutics Reports Second Quarter 2020 Financial Results and Business Updates

CHICAGO and BELOIT, Wis., June  30, 2020  (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (Chicago, IL) and NorthStar Medical Radioisotopes, LLC (Beloit, WI) announced today that a provisional patent application entitled “Precision Radioimmunotherapeutic Targeting of the Urokinase Plasminogen Activator Receptor (uPAR) for Treatment of Severe COVID-19 Disease” has been filed with the U.S. Patent and Trademark Office (USPTO).

Monopar and NorthStar Announce Filing of Provisional Patent Protecting Development and Use of Radio-Immuno-Therapeutics (RITs) Targeting Severe COVID-19 Through uPAR

Monopar Therapeutics (NASDAQ: MNPR) shares are trading higher on Tuesday, after the company announced it joined forces with NorthStar to develop a radio-immuno-therapeutics to target severe coronavirus.

Why Monopar's Stock Is Trading Higher Today

News for Monopar Therapeutics Stock (MNPR)